Europe|Health
Alzheimer's drug from Eisai and Biogen rejected in Europe
The European Union's drugs regulator has rejected Eisai and Biogen's Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain
July 26, 2024Your subscription includes
Unlimited Access to All Content from
The Los Angeles Post
The European Union's drugs regulator has rejected Eisai and Biogen's Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain
July 26, 2024